Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Related Citations for PubMed (Select 21724699)

1.

Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.

Khanna D, Furst DE, Maranian P, Seibold JR, Impens A, Mayes MD, Clements PJ, Getzug T, Hays RD.

J Rheumatol. 2011 Sep;38(9):1920-4. doi: 10.3899/jrheum.110225. Epub 2011 Jul 1.

2.

Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.

Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, Clements PJ, Getzug T, Fathi N, Bechtel A, Furst DE.

Arthritis Rheum. 2009 Sep 15;61(9):1257-63. doi: 10.1002/art.24730.

3.

Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.

Bodukam V, Hays RD, Maranian P, Furst DE, Seibold JR, Impens A, Mayes MD, Clements PJ, Khanna D.

Rheumatology (Oxford). 2011 Feb;50(2):330-4. doi: 10.1093/rheumatology/keq296. Epub 2010 Sep 30.

4.

Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument.

Khanna D, Hays RD, Park GS, Braun-Moscovici Y, Mayes MD, McNearney TA, Hsu V, Clements PJ, Furst DE.

Arthritis Rheum. 2007 Oct 15;57(7):1280-6.

5.

Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis.

Baron M, Hudson M, Steele R, Lo E; Canadian Scleroderma Research Group.

J Rheumatol. 2011 Sep;38(9):1925-30. doi: 10.3899/jrheum.110060. Epub 2011 Jul 1.

PMID:
21724704
6.

Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study.

Frech T, Hays RD, Maranian P, Clements PJ, Furst DE, Khanna D.

Rheumatology (Oxford). 2011 Jul;50(7):1280-7. doi: 10.1093/rheumatology/ker020. Epub 2011 Feb 15.

7.

Effect of gastrointestinal manifestations on quality of life in 87 consecutive patients with systemic sclerosis.

Omair MA, Lee P.

J Rheumatol. 2012 May;39(5):992-6. doi: 10.3899/jrheum.110826. Epub 2012 Apr 1.

PMID:
22467930
8.

Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis.

Nagaraja V, Hays RD, Khanna PP, Spiegel BM, Chang L, Melmed GY, Bolus R, Khanna D.

Arthritis Care Res (Hoboken). 2014 Nov;66(11):1725-30. doi: 10.1002/acr.22337.

PMID:
24692332
9.

Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis.

Bae S, Allanore Y, Furst DE, Bodukam V, Coustet B, Morgaceva O, Maranian P, Khanna D.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):57-63. Epub 2013 Jul 22.

PMID:
23910611
10.

Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.

Bae S, Allanore Y, Coustet B, Maranian P, Khanna D.

Clin Exp Rheumatol. 2011 Mar-Apr;29(2 Suppl 65):S15-21. Epub 2011 May 12.

PMID:
21586213
11.

Measuring response in the gastrointestinal tract in systemic sclerosis.

Khanna D, Nagaraja V, Gladue H, Chey W, Pimentel M, Frech T.

Curr Opin Rheumatol. 2013 Nov;25(6):700-6. doi: 10.1097/01.bor.0000434668.32150.e5. Review.

12.

Nutritional status and gastrointestinal symptoms in systemic sclerosis patients.

Murtaugh MA, Frech TM.

Clin Nutr. 2013 Feb;32(1):130-5. doi: 10.1016/j.clnu.2012.06.005. Epub 2012 Jul 4.

PMID:
22770637
13.

Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch.

Meijs J, Pors D, Vliet Vlieland TP, Huizinga TW, Schouffoer AA.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-41-8. Epub 2014 Jun 30.

PMID:
24984228
14.

Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study.

Khanna D, Tseng CH, Furst DE, Clements PJ, Elashoff R, Roth M, Elashoff D, Tashkin DP; for Scleroderma Lung Study Investigators.

Rheumatology (Oxford). 2009 Dec;48(12):1537-40. doi: 10.1093/rheumatology/kep284. Epub 2009 Sep 23.

15.

The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma.

Sekhon S, Pope J; Canadian Scleroderma Research Group, Baron M.

J Rheumatol. 2010 Mar;37(3):591-8. doi: 10.3899/jrheum.090375. Epub 2010 Jan 15.

PMID:
20080913
16.

Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis.

Nietert PJ, Mitchell HC, Bolster MB, Curran MY, Tilley BC, Silver RM.

J Rheumatol. 2005 Jan;32(1):51-7.

PMID:
15630725
17.

Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis.

Khanna D, Furst DE, Wong WK, Tsevat J, Clements PJ, Park GS, Postlethwaite AE, Ahmed M, Ginsburg S, Hays RD; Scleroderma Collagen Type 1 Study Group.

Qual Life Res. 2007 Aug;16(6):1083-92. Epub 2007 Apr 3.

PMID:
17404896
18.

Low-dose naltrexone for pruritus in systemic sclerosis.

Frech T, Novak K, Revelo MP, Murtaugh M, Markewitz B, Hatton N, Scholand MB, Frech E, Markewitz D, Sawitzke AD.

Int J Rheumatol. 2011;2011:804296. doi: 10.1155/2011/804296. Epub 2011 Sep 12.

19.

Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre.

Thoua NM, Bunce C, Brough G, Forbes A, Emmanuel AV, Denton CP.

Rheumatology (Oxford). 2010 Sep;49(9):1770-5. doi: 10.1093/rheumatology/keq147. Epub 2010 Jun 8.

20.

Lower gastrointestinal symptoms and quality of life in patients with systemic sclerosis: a population-based study.

Franck-Larsson K, Graf W, Rönnblom A.

Eur J Gastroenterol Hepatol. 2009 Feb;21(2):176-82. doi: 10.1097/MEG.0b013e32831dac75.

PMID:
19212206
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk